**OPKO Health, Inc. Reports Annual Financial Results**

OPKO Health, Inc. (NASDAQ: OPK) has released its financial results for the year ended December 31, 2025, reporting total revenues of $606.9 million, a 15% decrease compared to $713.1 million in 2024. The decline was primarily attributed to a $110.4 million decrease in revenue from services within the diagnostics segment, stemming from the sale of BioReference's lab and oncology operations. Revenue from products increased slightly by 1% to $156.9 million, while revenue from the transfer of intellectual property and other sources increased by 3% to $79.7 million. The company's loss from operations was $117.4 million, a 23% improvement compared to a loss of $152.1 million in the previous year.

The diagnostics segment reported revenues of $370.3 million, a 23% decrease from $480.7 million in 2024, with an operating income of $21.3 million compared to an operating loss of $24.1 million in the prior year. The pharmaceuticals segment recorded revenues of $236.6 million, a 2% increase from $232.5 million in 2024, but experienced an operating loss of $98.3 million, compared to a loss of $86.8 million in the previous year. Research and development expenses increased by 18% to $124.0 million, driven by investments in immuno-oncology and infectious disease programs, as well as hGH-CTP and Rayaldee development. The company's net loss for the year was $225.7 million, or $0.30 per share, compared to a net loss of $53.2 million, or $0.08 per share, in 2024.

Strategic developments during the year included the completion of the sale of BioReference's oncology diagnostics business to Labcorp for up to $225 million, and the completion of a private offering of $250 million aggregate principal amount of senior secured notes. OPKO also repurchased 34.6 million shares of its common stock for $47.0 million. ModeX Therapeutics, a subsidiary of OPKO, entered into a strategic license and collaboration agreement with Regeneron to discover and develop multispecific antibodies, and announced dosing of the first patient in a Phase 1 study of an EBV vaccine candidate.

As of December 31, 2025, OPKO Health had cash, cash equivalents, and restricted cash totaling $382.7 million. The company believes its current cash position is sufficient to meet anticipated cash requirements for operations and debt service beyond the next 12 months. OPKO Health is focused on advancing its ModeX multispecific pipeline, expanding its portfolio through strategic collaborations, maximizing the global value of NGENLA®, executing on Rayaldee's international expansion, and optimizing its specialty diagnostics business. The company's workforce consisted of 2,275 full-time employees worldwide as of December 31, 2025.

About OPKO HEALTH, INC.

OPKO Health is a diversified healthcare company specializing in pharmaceuticals, diagnostics, and biologics. It develops and commercializes therapies like long-acting growth hormone (NGENLA) and treatments for kidney disease, while operating diagnostic labs and advanced biotech pipelines. Its core markets include the U.S., Europe, Asia, and Latin America, leveraging proprietary technologies, strategic partnerships, and a global footprint to address unmet medical needs in endocrinology, oncology, infectious diseases, and personalized medicine.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.